ValuEngine upgraded shares of Coherus Biosciences (NASDAQ:CHRS) from a strong sell rating to a sell rating in a research note issued to investors on Wednesday, January 3rd.

Several other analysts have also weighed in on CHRS. Zacks Investment Research raised Coherus Biosciences from a hold rating to a buy rating and set a $11.00 target price for the company in a report on Wednesday, January 3rd. BidaskClub raised Coherus Biosciences from a sell rating to a hold rating in a research report on Thursday, December 21st. Citigroup reissued a buy rating and set a $23.00 price objective on shares of Coherus Biosciences in a report on Tuesday, November 7th. Credit Suisse Group restated an outperform rating and set a $17.00 target price (down previously from $24.00) on shares of Coherus Biosciences in a research note on Wednesday, September 27th. Finally, Cowen reiterated an outperform rating and issued a $45.00 price objective on shares of Coherus Biosciences in a research report on Friday, September 8th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company. The company currently has a consensus rating of Buy and an average target price of $29.67.

Shares of Coherus Biosciences (NASDAQ CHRS) opened at $12.05 on Wednesday. The company has a current ratio of 5.46, a quick ratio of 5.46 and a debt-to-equity ratio of 1.84. Coherus Biosciences has a twelve month low of $8.05 and a twelve month high of $28.60.

Coherus Biosciences (NASDAQ:CHRS) last released its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($1.09) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.83) by ($0.26). Coherus Biosciences had a negative return on equity of 582.31% and a negative net margin of 73.89%. equities research analysts anticipate that Coherus Biosciences will post -4.39 EPS for the current fiscal year.

A number of hedge funds have recently bought and sold shares of CHRS. Schwab Charles Investment Management Inc. lifted its holdings in Coherus Biosciences by 20.2% during the second quarter. Schwab Charles Investment Management Inc. now owns 161,366 shares of the biotechnology company’s stock worth $2,316,000 after acquiring an additional 27,064 shares in the last quarter. Rhumbline Advisers lifted its holdings in Coherus Biosciences by 16.9% during the second quarter. Rhumbline Advisers now owns 42,282 shares of the biotechnology company’s stock worth $607,000 after acquiring an additional 6,105 shares in the last quarter. SG Americas Securities LLC lifted its holdings in Coherus Biosciences by 32.7% during the second quarter. SG Americas Securities LLC now owns 7,244 shares of the biotechnology company’s stock worth $104,000 after acquiring an additional 1,785 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Coherus Biosciences by 2.8% in the second quarter. Bank of New York Mellon Corp now owns 169,840 shares of the biotechnology company’s stock valued at $2,437,000 after purchasing an additional 4,700 shares in the last quarter. Finally, Legal & General Group Plc lifted its holdings in shares of Coherus Biosciences by 12.6% in the second quarter. Legal & General Group Plc now owns 9,341 shares of the biotechnology company’s stock valued at $134,000 after purchasing an additional 1,046 shares in the last quarter. Hedge funds and other institutional investors own 81.48% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was originally posted by Marea Informative and is the sole property of of Marea Informative. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://www.mareainformativa.com/coherus-biosciences-chrs-upgraded-to-sell-by-valuengine-updated-updated-updated/126457/.

About Coherus Biosciences

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Coherus Biosciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.